Ocular Therapeutix Inc. (OCUL)
Ocular Therapeutix: Betting On Axpaxli For A Major Market Breakthrough
Ocular Therapeutix is a biopharmaceutical company with a successful commercial product, Dextenza, generating $57.9 million in revenue in 2023. The company's main value driver is Axpaxli, an axitinib intravitreal implant in phase 3 trials for wet age-related macular degeneration (wet AMD). The company has a strong financial position with $482.9 million in cash and a 3.5-year cash runway, minimizing dilution risk.
Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results
Ocular Therapeutix has provided promising updates on its clinical trials for Axpaxli and Paxtrava, utilizing its Elutyx drug-eluting platform. The company has appointed a new CEO and raised funds, extending its cash runway until 2028. Ocular's pipeline includes treatments for wet-AMD, diabetic retinopathy, glaucoma, and other eye conditions, with potential for significant revenue growth.
